


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
GRANT OF SHARE AWARDS PURSUANT TO
RESTRICTED SHARE AWARD SCHEME

Reference is made to the announcement of Sino Biopharmaceutical Limited (the “**Company**”) dated 5 January 2018 (the “**Announcement**”) in relation to the adoption of the restricted share award scheme (the “**Scheme**”) by the Company. Unless otherwise defined herein, capitalised terms used in this announcement have the same meanings as defined in the Announcement.

GRANT OF SHARE AWARDS PURSUANT TO THE RESTRICTED SHARE AWARD SCHEME

The Company recently granted a total of 6,854,834 share awards (the “**Share Awards**”) to 15 eligible persons who are employees of the Company. None of them is a director, chief executive or substantial shareholder of the Company or any of their associate (as defined in the Listing Rules) or a connected person of the Company. Vesting of these Shares Awards will be subject to such vesting conditions as the Board may prescribe.

PURPOSES AND OBJECTIVES

1. To recognize the contribution of employees and to motivate them to continue to support the Company’s operations and development, and to work for the enhancement of the value of the Company and the interests of all shareholders of the Company;
2. To enable the Company to adopt a flexible approach to motivate and retain employees, and to attract suitable talents for the further development of the Company, so as to promote the long-term development of the Company; and

3. The grant of the Shares Awards at this point of time demonstrates the Company's confidence in its business development prospects and its shares' intrinsic value.

The restricted share award scheme of the Company shall be funded solely by existing Shares purchased by the Company under the Scheme, and this grant of Share Awards is only subject to the disclosure requirements under Rule 17.12 of the Listing Rules.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 17 October 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.